Search Results for overcoming-cancers-resistant-to-her-2-antibodies

This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.

Author: Benjamin Bonavida

Publisher: Sensitizing Agents for Cancer

ISBN: 0128164085

Category: Medical

Page: 250

View: 973

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
2019-12-15 By Benjamin Bonavida

The primary focus is on novel approaches to overcome HER2 therapy resistance in the treatment of breast cancer. We discuss approaches to target HER2 with antibodies, tyrosine kinase inhibitors, or antibody-drug conjugates, ...

Author: Myron R. Szewczuk

Publisher: Springer

ISBN: 9783030214777

Category: Medical

Page: 320

View: 614

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
2019-07-15 By Myron R. Szewczuk

Strategies to Overcome Resistance Benjamin Bonavida. HER2/HER3 heterodimerization and, therefore, does not block signaling from these heterodimers [104]. Pertuzumab, an anti-HER2 humanized MAb that binds to an epitope located in domain ...

Author: Benjamin Bonavida

Publisher: Springer Science & Business Media

ISBN: 9781461476542

Category: Medical

Page: 202

View: 474

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
2013-08-04 By Benjamin Bonavida

In addition to interactions between HER2 and IGF-1R, heterodimerization between HER family members, ... resulting in sustained Akt activation.62,63 Novel Therapeutics: Overcoming Trastuzumab Resistance Many agents have been developed in ...

Author: Bruce A. Chabner

Publisher: Lippincott Williams & Wilkins

ISBN: 9781451148206

Category: Medical

Page: 848

View: 395

Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.
2011-12-07 By Bruce A. Chabner

In addition to the HER family receptor tyrosine kinases that confer resistance to HER2-targeted therapies, ... Therefore, combined targeting of other receptors is currently under consideration to overcome trastuzumab resistance.

Author: Dong-Young Noh

Publisher: Springer Nature

ISBN: 9789813296206

Category: Medical

Page: 630

View: 150

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.
2021-05-13 By Dong-Young Noh

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways.

Author: Banujan Balachandran


ISBN: OCLC:922055022



View: 145

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination therapies. However, the majority of advanced HER-2 positive breast cancer patients still develop resistance to the therapy by the end of the first year or present de novo resistance. For this reason, it is important to continue to investigate therapies to give in combination with trastuzumab to improve progression-free survival and overall survival in this clinical setting. Two Phase II Astra Zeneca compounds: AZD0530, a dual Src and Abl kinase inhibitor and AZD8931, a pan-erbb tyrosine kinase inhibitor abrogating EGFR-, HER-2-, and HER-3-mediated signaling were explored in this context using established trastuzumab-naïve and trastuzumab-resistant cell lines. AZD0530 was not effective when administered alone and any combinations with trastuzumab showed positive responses only in those models in which some form of response to AZD0530 alone had been seen. Clinically-relevant responses to AZD8931 were seen in all cell lines tested and for this reason a head-to-head comparison was carried out with lapatinib, the FDA-approved therapy for patients progressing on trastuzumab. AZD8931 alone and in combination with trastuzumab worked effectively to stop proliferation and induce cell death in both trastuzumab-naïve and trastuzumab-resistant cell lines at clinically relevant doses. AZD8931 had similar activity to lapatinib in the SKBR3-based ER-negative cell lines, but was less active in the BT474-based ER-positive cell lines. From this study, it appears AZD8931 is a therapeutic candidate for overcoming trastuzumab resistance but further investigation is required, before translation into the clinical setting, including the use of animal models of trastuzumab-resistance, specifically in the ER-negative subtype." --

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis ... Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ...

Author: Goli Samimi

Publisher: Academic Press

ISBN: 9780128198414

Category: Science

Page: 188

View: 436

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field
2020-11-06 By Goli Samimi

The presence of these mutations in HER2-amplified cancer cells confers resistance to trastuzumab or lapatinib [7 ... and combining two HER2 antibodies, trastuzumab and pertuzumab, prolonged survival longer than trastuzumab alone [22].

Author: Kasirajan Ayyanathan

Publisher: CRC Press

ISBN: 9781482299458

Category: Medical

Page: 410

View: 960

This title includes a number of Open Access chapters. Cell signaling is a field that studies how cells communicate to control basic activities and respond to their environment. When looking specifically at cancer cells, researchers can gain a better understanding of cancer on a cellular level, an understanding that may have implications for developing new treatments. The current volume provides an overview of the field and how various cell biology techniques are used to better understand cancer on a cellular level. This easily accessible reference volume offers a comprehensive look at the field of cancer cell signaling. Edited by a researcher from Florida Atlantic University, Cancer Cell Signaling: Targeting Signaling Pathways Towards Therapeutic Approaches to Cancer is an authoritative and easy-to-use reference.
2014-06-20 By Kasirajan Ayyanathan

“Trastuzumab has shown significant efficacy in HER2-overexpressing breast cancers and is approved for patients whose tumors ... these aberrations as therapeutic targets that potentially overcome resistance to trastuzumab is highlighted.


Publisher: ScholarlyEditions

ISBN: 9781481605168

Category: Medical

Page: 105

View: 349

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at
2012-12-26 By

(2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that ... (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin.

Author: Robert A. Meyers

Publisher: John Wiley & Sons

ISBN: 9783527681860

Category: Science

Page: 940

View: 835

The first complete overview of progress in the field. The two volumes contain selected articles from the prestigious online Encyclopedia of Molecular Cell Biology and Molecular Medicine, fully updated and enriched with numerous new contributions from many eminent scientists. Divided into three parts, the first gives a thorough introduction to cancer biology, while Part Two covers therapeutic approaches for all major forms of cancer, and the third part deals with cancer diagnostics. The result is a one-stop resource for advanced students, postdoctoral researchers and start-up companies.
2016-04-29 By Robert A. Meyers